Early detection of liver steatosis by magnetic resonance imaging in rats infused with glucose and Intralipid solutions and correlation to insulin levels

Metabolism: Clinical and Experimental

Volumn 62, Issue 12, 2013, Pages 1850-1857

  D'Assignies, Gaspard ^a,b   Fontés, Ghislaine ^a,c,d   Kauffmann, Claude ^a   Latour, Martin ^a,c   Gaboury, Louis ^c   Boulanger, Yvan ^a   Van Beers, Bernard E ^b   Soulez, Gilles ^f   Poitout, Vincent ^a,c,d,e   Tang, An ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b BEAUJON HOSPITAL   (France)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

^f NOTRE DAME HOSPITAL   (Canada)

Author keywords

Diabetes mellitus; Hepatic steatosis; Insulin; MRI; Nonalcoholic fatty liver disease

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; INTRALIPID; LIPID EMULSION; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FATTY LIVER; GOTO KAKIZAKI RAT; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; INTERMETHOD COMPARISON; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; RAT; WISTAR RAT;

DIABETES MELLITUS; FAT FRACTION; FF; GLU+IL; GLUCOSE+INTRALIPID; HEPATIC STEATOSIS; IN-PHASE; INSULIN; IP; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MR; MRI; MRS; NAFLD; NASH; NONALCOHOLIC FATTY LIVER DISEASE; NONALCOHOLIC STEATOHEPATITIS; OP; OPPOSED-PHASE; RECEIVER OPERATING CHARACTERISTIC; ROC; SAL; SALINE;

ANIMALS; C-PEPTIDE; DIABETES MELLITUS; FAT EMULSIONS, INTRAVENOUS; FATTY LIVER; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; INFUSIONS, INTRAVENOUS; INSULIN; LIPID METABOLISM; LIVER; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; RATS; RATS, WISTAR; ROC CURVE; TISSUE FIXATION;

EID: 84888002840     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.08.003     Document Type: Article

References (42)

1. M. Shibata, Y. Kihara, and M. Taguchi Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men Diabetes Care 30 11 2007 2940 2944
2. J.C. Bae, E.J. Rhee, and W.Y. Lee Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study Diabetes Care 34 3 2011 727 729
3. A. Kotronen, L. Juurinen, and A. Hakkarainen Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects Diabetes Care 31 1 2008 165 169
4. Z.M. Younossi, M. Otgonsuren, and C. Venkatesan In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not Metabolism 62 3 2013 352 360
5. L.A. Adams, and J.A. Talwalkar Diagnostic evaluation of nonalcoholic fatty liver disease J Clin Gastroenterol 40 3 Suppl 1 2006 S34 S38
6. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 16 2002 1221 1231
7. K. Cusi Nonalcoholic fatty liver disease in type 2 diabetes mellitus Curr Opin Endocrinol Diabetes Obes 16 2 2009 141 149
8. N.C. Leite, C.A. Villela-Nogueira, and V.L. Pannain Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors Liver Int 31 5 2011 700 706
9. D. Preiss, and N. Sattar Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations Clin Sci (Lond) 115 5 2008 141 150
10. H.B. El-Serag, T. Tran, and J.E. Everhart Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma Gastroenterology 126 2 2004 460 468
11. K. Gariani, J. Philippe, and F.R. Jornayvaz Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside Diabetes Metab 39 1 2013 16 21
12. M. Jacobs, M.M. van Greevenbroek, and C.J. van der Kallen The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] Study) Metabolism 60 7 2011 969 975
13. A.M. El-Badry, S. Breitenstein, and W. Jochum Assessment of hepatic steatosis by expert pathologists: the end of a gold standard Ann Surg 250 5 2009 691 697
14. V. Ratziu, F. Charlotte, and A. Heurtier Sampling variability of liver biopsy in nonalcoholic fatty liver disease Gastroenterology 128 7 2005 1898 1906
15. A. Regev, M. Berho, and L.J. Jeffers Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection Am J Gastroenterol 97 10 2002 2614 2618
16. R. Belfort, S.A. Harrison, and K. Brown A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 355 22 2006 2297 2307
17. L.S. Szczepaniak, P. Nurenberg, and D. Leonard Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population Am J Physiol Endocrinol Metab 288 2 2005 E462 E468
18. S.B. Reeder, P.M. Robson, and H. Yu Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling J Magn Reson Imaging 29 6 2009 1332 1339
19. T. Yokoo, M. Bydder, and G. Hamilton Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T Radiology 251 1 2009 67 76
20. d'Assignies G, Ruel M, Khiat A, et al. Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods. Eur Radiol 2009;19(8): 2033-40.
21. B. Guiu, J.M. Petit, and R. Loffroy Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy Radiology 250 1 2009 95 102
22. G. Fontes, B. Zarrouki, and D.K. Hagman Glucolipotoxicity age-dependently impairs beta cell function in rats despite a marked increase in beta cell mass Diabetologia 53 11 2010 2369 2379
23. D.K. Hagman, M.G. Latour, and S.K. Chakrabarti Cyclical and alternating infusions of glucose and Intralipid in rats inhibit insulin gene expression and Pdx-1 binding in islets Diabetes 57 2 2008 424 431
24. S.W. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra Magn Reson Med 30 6 1993 672 679
25. E. Hijona, J. Sanchez-Gonzalez, and J.M. Alustiza Accurate fat fraction quantification by multiecho gradient-recalled-echo magnetic resonance at 1.5 T in rats with nonalcoholic fatty liver disease Eur J Radiol 81 6 2011 1122 1127
26. C.D. Hines, H. Yu, and A. Shimakawa Quantification of hepatic steatosis with 3-T MR imaging: validation in ob/ob mice Radiology 254 1 2010 119 128
27. H.A. Marsman, M. Heger, and J.J. Kloek Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by (1) H-magnetic resonance spectroscopy in a rat model J Gastroenterol Hepatol 26 2 2010 356 363
28. F. Fischbach, and H. Bruhn Assessment of in vivo 1 h magnetic resonance spectroscopy in the liver: a review Liver Int 28 3 2008 297 307
29. D. Joy, V.R. Thava, and B.B. Scott Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 15 5 2003 539 543
30. A. Kotronen, L. Juurinen, and M. Tiikkainen Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes Gastroenterology 135 1 2008 122 130
31. A. Seppala-Lindroos, S. Vehkavaara, and A.M. Hakkinen Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men J Clin Endocrinol Metab 87 7 2002 3023 3028
32. D. Ardigo, F. Numeroso, and S. Valtuena Hyperinsulinemia predicts hepatic fat content in healthy individuals with normal transaminase concentrations Metabolism 54 12 2005 1566 1570
33. R. Taylor Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause Diabetologia 51 10 2008 1781 1789
34. E. Bugianesi, C. Zannoni, and E. Vanni Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 36 3 2004 165 173
35. S. Chitturi, S. Abeygunasekera, and G.C. Farrell Nash and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome Hepatology 35 2 2002 373 379
36. G. Perseghin, R. Bonfanti, and S. Magni Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease Am J Physiol Endocrinol Metab 291 4 2006 E697 E703
37. H.Z. Lin, S.Q. Yang, and C. Chuckaree Metformin reverses fatty liver disease in obese, leptin-deficient mice Nat Med 6 9 2000 998 1003
38. K.F. Petersen, S. Dufour, and D. Befroy Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes Diabetes 54 3 2005 603 608
39. T. Tsuchida, M. Shiraishi, and T. Ohta Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-ay mice Metabolism 61 7 2012 944 953
40. E. Sofer, M. Boaz, and Z. Matas Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial Metabolism 60 9 2011 1278 1284
41. H.A. Marsman, J.R. van Werven, and A.J. Nederveen Noninvasive quantification of hepatic steatosis in rats using 3.0 T 1H-magnetic resonance spectroscopy J Magn Reson Imaging 32 1 2010 148 154
42. J.R. van Werven, H.A. Marsman, and A.J. Nederveen Hepatic lipid composition analysis using 3.0-T MR spectroscopy in a steatotic rat model Magn Reson Imaging 30 1 2012 112 121